Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers

Mlynarsky, Liat; Bejarano‐Achache, Idit; Muszkat, Mordechai; Caraco, Yoseph

doi:10.1007/s00228-011-1143-z

Cited by 8 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4][5] Genetic variations in cytochrome P450-4F2 (CYP4F2), g-glutamyl carboxylase (GGCX), epoxide hydrolase 1 (EPHX1), calumenin (Calu), factor IX (F9), and factor VII (F7) gene also have shown subsidiary association with warfarin response. [6][7][8][9][10][11][12] Other nongenetic factors including ethnicity, age, body mass index, weight, and gender are also known to have a minor role in warfarin sensitivity. [13][14][15][16][17][18][19] Based on pharmacogenetics, clinical, and demographic factors, population-based warfarin pharmacogenomic algorithms have been generated for various ethnic groups.…”

Section: Introductionmentioning

confidence: 99%

Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients

Gaikwad

Ghosh

Avery

et al. 2017

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

The main aim of this study was to screen various genetic and nongenetic factors that are known to alter warfarin response and to generate a model to predict stable warfarin maintenance dose for Indian patients. The study comprised of 300 warfarin-treated patients. Followed by extensive literature review, 10 single-nucleotide polymorphisms, that is, VKORC1-1639 G>A (rs9923231), CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910), FVII R353Q (rs6046), GGCX 12970 C>G (rs11676382), CALU c.*4A>G (rs1043550), EPHX1 c.337T>C (rs1051740), GGCX: c.214+597G>A (rs12714145), GGCX: 8016G>A (rs699664), and CYP4F2 V433M (rs2108622), and 5 nongenetic factors, that is, age, gender, smoking, alcoholism, and diet, were selected to find their association with warfarin response. The univariate analysis was carried out for 15 variables (10 genetic and 5 nongenetic). Five variables, that is, VKORC1-1639 G>A, CYP2C9*2, CYP2C9*3, age, and diet, were found to be significantly associated with warfarin response in univariate analysis. These 5 variables were entered in stepwise and multiple regression analysis to generate a prediction model for stable warfarin maintenance dose. The generated model scored R of .67, which indicates that this model can explain 67% of warfarin dose variability. The generated model will help in prescribing more accurate warfarin maintenance dosing in Indian patients and will also help in minimizing warfarin-induced adverse drug reactions and a better quality of life in these patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients

Gaikwad

Ghosh

Avery

et al. 2017

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…12,13 Warfarin doses vary considerably between patients, with Factor VII polymorphism thought to be mainly responsible, although ambient temperature plays a role as well. 14,15 However, not all variabilities are explained by these and as of yet the process is not fully understood. The high ambient temperature in Kuwait, similar to many parts in Africa, may have likely contributed to the exaggerated response to warfarin seen in these three cases.…”

Section: Discussionmentioning

confidence: 99%

Non-traumatic intramural hematomas in patients on anticoagulant therapy: Report of three cases and overview of the literature

Bekheit

AlaaSallam

Khafagy

et al. 2014

African Journal of Emergency Medicine

View full text Add to dashboard Cite

“…Host factors like age and weight as well as environmental factors like diet and the use of interfering medications account for a portion of the variation in warfarin response [16]. FVII gene polymorphisms may alter the responsiveness of warfarin therapy [11]. By combining host, environmental and genetic markers into a single model, some 50-60% of the variability in warfarin maintenance dose could be accounted for [16].…”

Section: Discussionmentioning

confidence: 99%

Impact of Factor VII Polymorphism on Responsiveness to Warfarin Anticoagulant Therapy

Shaaban,

Serogy,

Zahra

et al. 2023

JAMMR

View full text Add to dashboard Cite

Background: Oral anticoagulants (OAs) are drugs prescribed to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients, and to treat and decrease the incidence of deep vein thrombosis and pulmonary embolism. We aimed to clarify the impact of factor VII (FVII) polymorphism on the extent of anticoagulation exerted by warfarin therapy. Methods: The study was performed on 30 patients on warfarin therapy with international normalized ratio (INR) 2-3, 21 of them for cardiac causes, 2 of them for orthopedic causes and the remaining 7 patients for vascular causes. They were subjected to warfarin therapy (Marevan), laboratory investigations (Prothrombin time (PT) and INR, FVII activity by coagulometric method, plasma warfarin level (by high performance liquid chromatography), and detecting FVII polymorphism (-401G/T & -402 G/A) by polymerase chain reaction). Results: Regarding the coagulation indicators of the patients with various FVII- 402 genotypes, PT time was significantly lower in homozygous mutant than heterozygous (P=0.032). Also, it was non significantly lower than that of wild type. PT time was non significantly lower in wild type than heterozygous. PT activity was significantly higher in homozygous mutant than heterozygous (P=0.032). Also, it was non significantly higher than that of wild type. PT activity was non significantly higher in wild type than heterozygous. There was significant difference as regard warfarin sensitivity index (WSI) between wild type and homozygous mutant. Marevan dose was significantly lower in wild type than homozygous mutant and heterozygous. Regarding the coagulation indicators of the patients with various FVII -401 genotypes, WSI was lower in wild type than heterozygous and homozygous mutant, however, it was significantly different between wild type compared to homozygous and heterozygous genotypes (P<0.001). Marevan dose was significantly higher in wild type than homozygous mutant (P<0.001), and it was non significantly higher in heterozygous than homozygous mutant. Conclusions: Marevan dose was significantly lower in wild type than homozygous and heterozygous mutant as regard FVII -402 G/A, while regarding FVII -401 G/T, marevan dose was significantly higher in wild type than homozygous mutant. Polymorphisms in FVII genes may play a significant role in modulating the warfarin’s anticoagulant effect.

show abstract

Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 1/1 carriers

Cited by 8 publications

References 36 publications

Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients

Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients

Non-traumatic intramural hematomas in patients on anticoagulant therapy: Report of three cases and overview of the literature

Impact of Factor VII Polymorphism on Responsiveness to Warfarin Anticoagulant Therapy

Contact Info

Product

Resources

About